


AMENDMENTS

1. (Currently Amended) A compound of general formula A-(Y-ONO₂)_s (I) and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof, wherein


s is an integer equal to 1;

A is selected from the following β-adrenergic blockers residues of formula (II):




wherein

R₁ is



R₂ is



Z is -C(O)-[.];


Z₁ is H;

Y is a bivalent radical having the following meaning selected from the group consisting of:

a)

- straight or branched C₁-C₂₀ alkylene being optionally substituted with one or more of the substituents selected from the group consisting of: halogen atoms, hydroxy, -ONO₂ or T, wherein T is -OC(O)(C₁-C₁₀alkyl)-ONO₂, -O(C₁-C₁₀alkyl)-ONO₂;

b)



wherein:

n is an integer from 0 to 20,

n₁ is an integer from 1 to 20;


n₂, n₃, n₄ and n₅ are integers equal or different from each other, equal to 0 or 1,


R³ and R⁴ are independently selected from H or CH₃,

Y¹ is -CH₂- or -(CH₂)_{na}-CH=CH- wherein na is an integer from 0 to 20;

X₁ is -WC(O)- or -C(O)W-, wherein W is oxygen, sulfur or NH; and

c)





(VII)

wherein

X₂ is O or S,

n10a, n10 and n12 are integer independently selected from 0 to 20,

n11 is an integer from 0 to 6;


R¹¹ is H, CH₃ or nitrooxy group;

R^{11a} is CH₃ or nitrooxy group;

and wherein (Y-ONO₂)_s bonds with Z and/or [[Z1]] Z₁ of formula (II).

Claims 2-3. (Canceled).

4. (Currently Amended) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim [[3]] 1 wherein Y is a straight or branched C₁-C₁₀ alkylene.
5. (Currently Amended) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim [[2]] 1 wherein Y is



(IV)


wherein


n is an integer from 0 to 20,

n1 is an integer from 1 to 20;

n₂, n₃, n₄ and n₅ are integers equal or different from each other, equal to 0 or 1;
R³ and R⁴ are independently selected from H or CH₃;
Y¹ is –CH₂– or –CH₂)_{na}–CH=CH– wherein na is an integer from 0 to 20;
X₁ is –WC(O)– or –C(O)W–, wherein W is oxygen, sulfur or NH.

6. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim 5 wherein
n₂, n₃, n₄, n₅ are equal to 0,
n₁ is 1,
n is an integer from 0 to 10,
Y¹ is CH₂.
7. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim 5 wherein
n, n₂, n₅ are 1,
n₃ and n₄ are equal to 0, and
n₁ is an integer from 1 to 10,
Y¹ is –(CH₂)_{na}–CH=CH– wherein na is 0,
X₁ is –WC(O)– wherein W is oxygen and X₁ is bound to the phenyl ring through the [C]₄,
R⁴ is CH₃ and the group (OR⁴) is bound to the phenyl ring through the [C]₃.
8. (Currently Amended) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim [[2]] 1 wherein
Y is





wherein

X₂ is O or S,


n10a, n10 and n12 are integers independently selected from 0 to 20;

n11 is an integer from 0 to 6;

R¹¹ is H, CH₃ or a nitrooxy group;

R^{11a} is CH₃ or a nitrooxy group.

9. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim 8 wherein Y is



wherein

X₂ is O or S,

n10a is an integer from 0 to 10

n11 are 0,

n12 is an integer from 1 to 10,

R¹¹ is H or a nitrooxy group;


wherein the -ONO₂ group is bound to the -(CH₂)_{n12}- group.


Claims 10-57. (Canceled).

58. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim 1 wherein Y is a straight or branched C₁-C₂₀ alkylene being optionally substituted with one or more of the substituents selected from the group consisting of halogen atoms, hydroxy, -ONO₂ or T, wherein T is -OC(O)(C₁-C₁₀alkyl)-ONO₂, -O(C₁-C₁₀alkyl)-ONO₂.
59. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim 58 wherein Y is a straight or branched C₃-C₆ alkylene.

Claims 60-80. (Canceled).

81. (Currently Amended) Compounds and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to any one of claims 1, 58 or 59 wherein the compounds are:





Claims 82-87. (Canceled).

88. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts according to claim 1, that is 4-(Nitrooxymethyl)benzoic acid 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanoate.

Claims 89-90. (Canceled).

91. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts according to any one of claims 1, 58 or 59, that is 6-(nitrooxy)hexanoic acid 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol hydrochloride.

Claims 92-94. (Canceled).

95. (Currently Amended) A medicament comprising a compound of formula (I) and/or the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof as defined in ~~any of claims~~ claim 1 to 94 ~~for use as medicament~~.
96. (Currently Amended) A method for the treatment or prophylaxis of hypertension, cardiovascular and vascular diseases using ~~Use of a drug comprising a~~ compound of formula (I) and/or the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof as defined in ~~any of claims~~ claim 1 to 94 ~~for preparing a drug that can be employed in the treatment or prophylaxis of hypertension, cardiovascular and vascular diseases~~.
97. (Currently Amended) A method for the treatment of glaucoma and elevated intraocular pressure using ~~Use of a drug comprising a~~ compound of formula (I) and/or the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof as defined in ~~any of claims~~ claim 1 to 94 ~~for preparing a drug that can be employed in the treatment of glaucoma and elevated intraocular pressure~~.
98. (Currently Amended) A pharmaceutical composition comprising a compound of formula (I) and/or the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof as defined in ~~any of claims~~ claim 1 to 94 and at least one pharmaceutical pharmaceutically acceptable carrier.